GreenLight Biosciences Holdings GRNA Stock
GreenLight Biosciences Holdings Price Chart
GreenLight Biosciences Holdings GRNA Financial and Trading Overview
GreenLight Biosciences Holdings stock price | 0.3 USD |
Previous Close | 0.29 USD |
Open | 0.29 USD |
Bid | 0 USD x 1800 |
Ask | 0 USD x 1400 |
Day's Range | 0.29 - 0.29 USD |
52 Week Range | 0.18 - 5.9 USD |
Volume | 627.91K USD |
Avg. Volume | 509.63K USD |
Market Cap | 43.68M USD |
Beta (5Y Monthly) | 1.422001 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 0.45 USD |
GRNA Valuation Measures
Enterprise Value | 89.06M USD |
Trailing P/E | N/A |
Forward P/E | -0.39452052 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 4.2235446 |
Price/Book (mrq) | 1.9862069 |
Enterprise Value/Revenue | 8.611 |
Enterprise Value/EBITDA | -0.609 |
Trading Information
GreenLight Biosciences Holdings Stock Price History
Beta (5Y Monthly) | 1.422001 |
52-Week Change | -93.20% |
S&P500 52-Week Change | 20.43% |
52 Week High | 5.9 USD |
52 Week Low | 0.18 USD |
50-Day Moving Average | 0.3 USD |
200-Day Moving Average | 1.08 USD |
GRNA Share Statistics
Avg. Volume (3 month) | 509.63K USD |
Avg. Daily Volume (10-Days) | 526.01K USD |
Shares Outstanding | 151.68M |
Float | 72.05M |
Short Ratio | 4.59 |
% Held by Insiders | 42.90% |
% Held by Institutions | 26.85% |
Shares Short | 3.37M |
Short % of Float | 3.60% |
Short % of Shares Outstanding | 2.22% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -1493.50% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -81.77% |
Return on Equity (ttm) | -366.86% |
Income Statement
Revenue (ttm) | 10.34M USD |
Revenue Per Share (ttm) | 0.07 USD |
Quarterly Revenue Growth (yoy) | 1386.40% |
Gross Profit (ttm) | N/A |
EBITDA | -146159008 USD |
Net Income Avi to Common (ttm) | -157316992 USD |
Diluted EPS (ttm) | -1.11 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 32.35M USD |
Total Cash Per Share (mrq) | 0.21 USD |
Total Debt (mrq) | 77.43M USD |
Total Debt/Equity (mrq) | 352.96 USD |
Current Ratio (mrq) | 1.209 |
Book Value Per Share (mrq) | 0.145 |
Cash Flow Statement
Operating Cash Flow (ttm) | -118280000 USD |
Levered Free Cash Flow (ttm) | -107650248 USD |
Profile of GreenLight Biosciences Holdings
Country | United States |
State | MA |
City | Lexington |
Address | 29 Hartwell Avenue |
ZIP | 02421 |
Phone | 617 616 8188 |
Website | https://greenlightbiosciences.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | N/A |
GreenLight Biosciences Holdings operates as a pre-commercial stage biotechnology company in the United States of America. It provides cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of high-performing products to promote healthier plants, foods, and people. The company's plant and animal health pipeline includes Calantha for the Colorado potato beetle; Varroa mites, an RNA-based syrup that targets reproductive mites; Vegetable Caterpillar Complex, an dsRNA-based pesticide for the Diamond Back Moth; and Spider Mite Complex for the control of Tetranychus urticae. It also developing fungicides program for botrytis, fusarium, powdery mildew, downy mildew, Asian soybean rust, and rice blast; Gray Mold + for botrytis cinerea; Powdery mildew complex for the control of powdery mildew, caused by Erysiphe necator; and Mycotoxin control for Fusarium Head Blight, a cereal crop based diseases. In addition, the company also developing human health program comprising a phase I/II preclinical stage vaccine for COVID-19; and candidate selection vaccines for Shingles, and oncology. GreenLight Biosciences Holdings was formerly known as Environmental Impact Acquisition Corp. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
Q&A For GreenLight Biosciences Holdings Stock
What is a current GRNA stock price?
GreenLight Biosciences Holdings GRNA stock price today per share is 0.3 USD.
How to purchase GreenLight Biosciences Holdings stock?
You can buy GRNA shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for GreenLight Biosciences Holdings?
The stock symbol or ticker of GreenLight Biosciences Holdings is GRNA.
Which industry does the GreenLight Biosciences Holdings company belong to?
The GreenLight Biosciences Holdings industry is Biotechnology.
How many shares does GreenLight Biosciences Holdings have in circulation?
The max supply of GreenLight Biosciences Holdings shares is 151.68M.
What is GreenLight Biosciences Holdings Price to Earnings Ratio (PE Ratio)?
GreenLight Biosciences Holdings PE Ratio is 0.00000000 now.
What was GreenLight Biosciences Holdings earnings per share over the trailing 12 months (TTM)?
GreenLight Biosciences Holdings EPS is 0 USD over the trailing 12 months.
Which sector does the GreenLight Biosciences Holdings company belong to?
The GreenLight Biosciences Holdings sector is Healthcare.
GreenLight Biosciences Holdings GRNA included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}